Product
- Home
- Product
Ritlecitinib CAS 1792180-81-4
Name: Ritlecitinib
CAS：1792180-81-4
Purity: 99% HPLC
Packaging : 1kg; 5kg; 25kg
| Product Name: | 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one |
| Synonyms: | PF-06651600;EOS-61890;1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one; 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2;CS-2733; PF-06651600;PF 06651600;PF06651600; 1-[(2S,5R)-2-methyl-5(7H-pyrrolo[2,3-d]pyrimidine-4-ylamino)-1-piperidinly]-2-propen-1-one malonate,PF06651600;Ritlecitinib |
| CAS: | 1792180-81-4 |
| MF: | C15H19N5O |
| MW: | 285.34 |
| EINECS: | 210-077-2 |
| Product Categories: | API;1 |
| Mol File: | 1792180-81-4.mol |
The main mechanism of action of Ritlecitinib involves the inhibition of Janus kinase.
Janus kinases are a class of enzymes that play a critical role in the immune system, particularly in signal transduction processes.
The immune system uses Janus kinase to transmit information and regulate the activity of immune cells.
In autoimmune diseases, the immune system mistakenly attacks and damages the body's own tissues, leading to inflammation and tissue damage.
By inhibiting Janus kinase, rituximab can interfere with abnormal activity of the immune system, reduce inflammation in the immune response, and potentially alleviate symptoms caused by autoimmune diseases. This mechanism of action makes rituximab a potential drug for treating autoimmune diseases.
purpose
Taking into account the history of drug development for alopecia areata, rituxinib is the second mature treatment for alopecia areata. It is a kinase inhibitor, and unlike the first drug, Olumiant, rituxinib is approved not only for adult patients but also for adolescent patients aged 12 and above.
Add a review
Your email address will not be published. Required fields are marked *